Certain genetic disorders cause widespread disease in the body, but the principle reason for illness and death in early childhood is failure of the blood system. We would like to study these genetic blood disorders by “turning back the clock” – using new technology in stem cell biology to take skin cells from patients with genetic blood disorders and return them to an embryonic-like state, wherein they regain the ability to form any type of cell in the body.... Read more about Suneet Agarwal, MD, PhD
Dana-Farber/Boston Children's Hospital Harvard Medical School
Hematopoietic stem cell (HSC) progeny can represent a vehicle for therapeutic molecule delivery to the Central Nervous System (CNS) upon transplantation in...
Alan Cantor's laboratory is focused on further elucidating the transcriptional mechanisms that regulate normal hematopoiesis and how they may be perturbed in certain inherited platelet disorders and hematologic malignancies.... Read more about Alan Cantor, MD, PhD
Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School | Broad Institute
The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients. The also focuses on a pre-... Read more about Benjamin L. Ebert, MD, PhD
Our laboratory is interested in the transcriptional regulation of normal blood cell development and leukemia. All blood cells arise from a small population...
Massachusetts General Hospital Harvard Medical School
The Hoggatt Laboratory is broadly interested in the stem cell niche regulatory mechanisms that govern tissue regeneration, particularly regulation by...
Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School
Our laboratory is interested in how immune responses in skin are initiated, and how T cell mediated memory responses occur in skin, and in particular a newly described population of antigen experienced T cells known as Resident Memory T Cell (TRM).... Read more about Thomas S. Kupper, MD
Massachusetts General Hospital Harvard Medical School
Our research focuses on using the zebrafish to better understand human cancer and to develop novel insights into how it is that tumors can be remade following conventional chemotherapeutic intervention. Uncovering the downstream molecular pathways that lead to relapse will be integral to identifying novel drugs for the treatment of cancer.... Read more about David M. Langenau, PhD
Chief of Staff, Office of the Dean of the Faculty of Medicine
M. William "Willy" Lensch works on behalf of the entire HMS community in a mission-centric manner. Before joining the HMS administration, Lensch served as...
Our group is working on cancer genetics, using the zebrafish genetic system to clarify developmental pathways subverted in human leukemias and solid...
Dana-Farber Cancer Institute Boston Children's Hospital Howard Hughes Medical Institute
The laboratory utilizes multidisciplinary approaches to understand how mammalian cells choose specific fates and how mutations in important transcriptional regulators lead to developmental defects or malignancy.... Read more about Stuart Orkin, MD
Dana-Farber Cancer Institute Brigham and Women's Hospital Harvard Medical School
Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used in the treatment of patients with hematologic malignancies, but continues to be associated with severe toxicities. Both the effectiveness and toxicity of HSCT are mediated by donor T-cells in the stem cell graft. Those T cells that target antigens expressed on recipient leukemia cells play an important role in eradicating residual tumor cells and preventing leukemia relapse after transplant. In contrast, T cells that target antigens expressed by normal tissues in the recipient are the primary mediators of graft versus host disease (GVHD) and thus lead to substantial toxicities. My laboratory focuses on the assessment of donor immune function after HSCT and characterization of the immune mechanisms responsible for graft versus leukemia (GVL) and GVHD.... Read more about Jerome Ritz, MD
